Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 2,913 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Event Clear all

Conditions: Hearing Loss, Unilateral Hearing Loss, Total Unilateral Deafness
Interventions: Sonitus SoundBite System, SoundBite Hearing System; Device
Lead sponsor: Sonitus Medical Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: San Jose, California

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: ELG; Device
Lead sponsor: XP Technology, LLC; Other
Eligibility: 25 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Springdale, Arkansas

Conditions: Arteriosclerosis
Interventions: clopidogrel (SR25990); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 45 Years and older
Enrollment: 15,603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atrial Fibrillation, Atrial Fibrillation Recurrent
Interventions: dronedarone 400 mg Oral Tablet, Placebo; Drug
Lead sponsor: Tulane University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Colorado Springs, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 1 more

Conditions: Cirrhosis of the Liver, Ascites, Spontaneous Bacterial Peritonitis
Interventions: Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin); Other
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Type 2
Interventions: I-START, Standard Insulin Administration Education; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Post-Operative Confusion, Neuroinflammatory Response, Alzheimer Disease
Interventions: Montreal Cognitive Assessment, Stroop Test, 4AT Delirium, Grooved Pegboard, NACC Cognitive Battery, ERP Testing, Blood Plasma and Serum sampling, Cerebral Spinal Fluid Sample; Behavioral · Diagnostic Test
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Solid Tumor Cancer
Interventions: Standard of Care chemotherapy Following an Algorithm, Standard of Care chemotherapy following CTCAE criteria; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 886 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Small Cell Lung Cancer
Interventions: ABBV-706, Topotecan, Lurbinectedin, Amrubicin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 37
States / cities: Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 32 more

Conditions: Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
Interventions: Epcoritamab; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 70
States / cities: Mobile, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 60 more

Conditions: Fibromyalgia
Interventions: Group Education and Stretching, Group Acupuncture; Behavioral · Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: ALTE
Interventions: Interview; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Post-traumatic Stress Disorder
Interventions: Mifepristone, d-Cycloserine, Placebo-matching Mifepristone, Placebo-matching d-Cycloserine (DCS); Drug
Lead sponsor: Roger K. Pitman, MD; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Pancreatic Neoplasm
Interventions: Ascorbate, Gemcitabine, radiation therapy; Drug · Radiation
Lead sponsor: Joseph J. Cullen, MD, FACS; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Breast Cancer, Breast Tumor, Cancer of Breast, Cancer of the Breast, Malignant Tumor of Breast, Tumors, Breast
Interventions: BC1 cell line, Bria-OTS regimen and CPI (tislelizumab), Bria-OTS regimen and CPI (tislelizumab) expansion cohort; Biological
Lead sponsor: BriaCell Therapeutics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Primary Immune Deficiency Disorder
Interventions: Octagam 5%, Other marketed IVIG product; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 27
States / cities: Granada Hills, California • Irvine, California • Los Angeles, California + 22 more

Conditions: Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Small Lymphocytic Lymphoma
Interventions: Pirtobrutinib, Venetoclax, Rituximab; Drug
Lead sponsor: Loxo Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 31
States / cities: Scottsdale, Arizona • San Diego, California • San Francisco, California + 25 more

Conditions: Healthy
Interventions: Yellow Fever Vaccine; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Interventions: Exercise, Calls and Newsletter; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Years and older · Male only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Autism Spectrum Disorder
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV, Cervical Cancer Stigma
Interventions: Neutral Video, Storytelling, Self disclosure, Combination, Video, Waitlist; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tetralogy of Fallot, Congenital Heart Disease
Interventions: Remote Heart Rhythm Monitoring; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Thromboembolic Events
Interventions: Not listed
Lead sponsor: Texas Cardiac Arrhythmia Research Foundation; Other
Eligibility: Not listed
Enrollment: 40 participants
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Metastatic Non-Small Cell Lung Cancer
Interventions: Pembrolizumab/Vibostolimab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed, Pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 739 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 12
States / cities: Colorado Springs, Colorado • Fort Collins, Colorado • Jacksonville, Florida + 8 more

Search by objective public record fields.

Long Term Safety of the Sonitus SoundBite System

The ELG Analysis of Glucose a Correlational to Blood Glucose Assay

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)

Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence

Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites

Insulin Start Therapy Application With Resources and Training

Neuroinflammation and Alzheimer's Pathology in POCD

Impact of Duffy-null Associated Neutropenia on Chemotherapy Dosing

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Complementary and Alternative Medicine (CAM) for Fibromyalgia

Apparent Life Threatening Events in Infants

Developing Memory Reconsolidation Blockers as Novel Posttraumatic Stress Disorder (PTSD) Treatments

A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Octagam 5% Versus Comparator Post Marketing Trial

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Yellow Fever Immune Response at Single Cell Resolution

PRescription Exercise for Older Men With Urinary Disease

A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder

RISE: Reducing Cancer and HIV Stigma Through Empowerment

Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot and Other Congenital Heart Diseases

Association of Genetic Variants With Risk of Stroke in Patients With Atrial Fibrillation Off-anticoagulation

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)